Pyxis Oncology Inc.

Last updated September 27, 2026

Organization details

Legal name
Pyxis Oncology Inc.
Ownership
Public
Status
Active
Sector (GICS)
Health Care
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Delaware
Headquarters city
Boston
Headquarters state / province
Massachusetts
Headquarters country
United States
Fiscal year end
December
Ticker symbol
PYXS
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001782223
EIN
83-1160910

Board of directors

Chief executives

Lara Sullivan · President and CEO
Dates unknown
Thomas Civik · Interim CEO Interim
Dates unknown

Director election results

Annual meeting of June 15, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

5 of this board's directors also sit on 6 other boards. 6 are in the same sector.

Network of Pyxis Oncology Inc.'s board connections Acrivon Therapeutics Inc. Acrivon Therapeutics I... Bolt Biotherapeutics Inc. Bolt Biotherapeutics I... CDT Equity Inc. CDT Equity Inc. Cybin Inc. Cybin Inc. Pliant Therapeutics Inc. Pliant Therapeutics In... Syndax Pharmaceuticals Inc. Syndax Pharmaceuticals... Darren S. Cline Darren S. Cline Freda C. Lewis-Hall Freda C. Lewis-Hall Jakob Dupont Jakob Dupont Michael A. Metzger Michael A. Metzger Santhosh Palani Santhosh Palani Pyxis Oncology Inc.
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
1 purchase by 1 insider
Sold, last 12 months
$107,100
1 sale by 1 insider
Date Insider Transaction Shares Price Value
Oct 1, 2026 GordonMD Global Investments LP 10% owner Open-market purchase +5,517,000 — —
Jun 30, 2026 Jakob Dupont Director Option exercise +35,000 $1.60 $56,000
Jun 30, 2026 Jakob Dupont Director Open-market sale −35,000 $3.06 $107,100
Mar 24, 2026 Wadhane Jitendra Officer (Prin Fin & Acct Officer) Grant or award +109,461 — —
Apr 21, 2025 Rachel Humphrey Director Open-market sale −13,896 $1.03 $14,313
Apr 17, 2025 Rachel Humphrey Director Open-market sale −200 $0.97 $194
Apr 14, 2025 Rachel Humphrey Director Open-market sale −1,400 $0.97 $1,358
Nov 26, 2024 Connealy Pamela Yanchik Officer (CFO & COO) Open-market purchase +5,450 $2.00 $10,900
Nov 26, 2024 Connealy Pamela Yanchik Officer (CFO & COO) Open-market purchase +83,400 $1.96 $163,464
Jun 7, 2024 Santhosh Palani Director Grant or award +6,000 — —
Mar 26, 2024 Connealy Pamela Yanchik Officer (CFO & COO) Grant or award +328,710 — —
Mar 26, 2024 Darren S. Cline Director Grant or award +35,219 — —
Mar 26, 2024 John L. Flavin Director Grant or award +35,219 — —
Mar 26, 2024 Freda C. Lewis-Hall Director Grant or award +35,219 — —
Mar 26, 2024 Jakob Dupont Director Grant or award +38,741 — —

Organizations in the same sector, closest in location and size first.

Questions about Pyxis Oncology Inc.

Who is the CEO of Pyxis Oncology Inc.?

Lara Sullivan is Pyxis Oncology Inc.'s President and CEO.

How many directors are on Pyxis Oncology Inc.'s board?

Pyxis Oncology Inc.'s board has 9 directors: Darren S. Cline, Freda C. Lewis-Hall, Jakob Dupont, John L. Flavin, Lara Sullivan, Michael A. Metzger, Rachel Humphrey, Santhosh Palani and Thomas Civik.

Are Pyxis Oncology Inc. insiders buying or selling shares?

Over the last 12 months, Pyxis Oncology Inc. insiders bought $0 of shares in 1 purchase and sold $107,100 of shares in 1 sale on the open market, as reported to the SEC on Forms 4 and 5.

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="pyxis-oncology-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.